GUD

Knight Therapeutics Announces Regulatory Submission for Tafasitamab in Brazil

Retrieved on: 
Thursday, October 6, 2022
ANVISA, GUD, Tafasitamab, Lenalidomide, Therapy, MorphoSys, TSX, ADCP, Annual report, Regulation of tobacco by the U.S. Food and Drug Administration, NASDAQ, Patient, Knight Therapeutics, Food, DLBCL, FC, Nature, Adult, Immunotherapy, Intention, GLOBE, ADCC, United Kingdom, Laboratorio de Energía Solar Termoeléctrica, ASCT, Lymphoid leukemia, Apoptosis, Pharmaceutical industry, Vaccine, Security (finance), Knight, Incyte, Uniting Medically Supervised Injecting Centre

We are delighted to reach this key milestone for tafasitamab in Brazil, said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics.

Key Points: 
  • We are delighted to reach this key milestone for tafasitamab in Brazil, said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics.
  • Upon approval, combination therapy with tafasitamab and lenalidomide will be an important new therapeutic option for eligible patients with relapsed or refractory DLBCL in Brazil.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .
  • Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2021 as filed on www.sedar.com .

Knight Therapeutics Inc. places No. 22 on The Globe and Mail's fourth-annual ranking of Canada's Top Growing Companies

Retrieved on: 
Friday, September 23, 2022
Health, The Globe and Mail, TSX, Policy, Journalism, Nature, Intention, Politics, Company, Optimism, Therapy, Business, Patient, CEO, GUD, Annual report, Laboratorio de Energía Solar Termoeléctrica, GLOBE, Globe, Woodbridge, Oil, Pharmaceutical industry, Publishing, Uniting Medically Supervised Injecting Centre, Report, Knight

MONTREAL, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (Knight or the Company) is pleased to announce it placed No.

Key Points: 
  • MONTREAL, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (Knight or the Company) is pleased to announce it placed No.
  • 22 on the 2022 Report on Business ranking of Canadas Top Growing Companies.
  • Canadas Top Growing Companies ranks Canadian companies on three-year revenue growth.
  • Canadas Top Growing Companies is an editorial ranking that was launched in 2019.

Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil

Retrieved on: 
Monday, August 15, 2022
Parkinson's disease, Internal medicine, Dementia, GLOBE, GUD, TSX, Rivastigmine, National university, Annual report, Caregiver, Marketing, Patient, Therapy, Acquisition, Alzheimer's disease, Associate, Nature, Intention, Federal University of Minas Gerais, Laboratorio museotecnico Goppion, UFMG, Pharmaceutical industry, Exelon, Novartis, Uniting Medically Supervised Injecting Centre, Knight

MONTREAL, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has assumed full commercial activities and is re-launching Exelon (rivastigmine) in Brazil following successful transfer of the marketing authorization.

Key Points: 
  • MONTREAL, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has assumed full commercial activities and is re-launching Exelon (rivastigmine) in Brazil following successful transfer of the marketing authorization.
  • Exelon is a prescription product that was first approved in 1997 and is currently registered and sold in approximately 90 countries.
  • Exelon is indicated for the symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's disease and Parkinson's disease.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .

Knight to Present at the Canaccord Genuity 42nd Annual Growth Conference

Retrieved on: 
Thursday, August 4, 2022
Annual report, Canaccord Genuity, GUD, Laboratorio de Energía Solar Termoeléctrica, Intention, GLOBE, Conference, TSX, Therapy, Nature, Uniting Medically Supervised Injecting Centre

MONTREAL, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Amal Khouri, Chief Business Officer, is scheduled to present at Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 11:00 am ET.

Key Points: 
  • MONTREAL, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Amal Khouri, Chief Business Officer, is scheduled to present at Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 11:00 am ET.
  • Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .
  • Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2021 as filed on www.sedar.com .

Notice of Knight Therapeutics' Second Quarter 2022 Results Conference Call

Retrieved on: 
Thursday, August 4, 2022
Intention, TSX, Therapy, Annual report, Nature, GUD, Laboratorio de Energía Solar Termoeléctrica, Uniting Medically Supervised Injecting Centre

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.

Key Points: 
  • Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .
  • Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2021 as filed on www.sedar.com .
  • Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information or future events, except as required by law.

Microbix Presenting STI Multiplex Test Controls at AACC

Retrieved on: 
Tuesday, July 26, 2022
Goal, TSX, Association, Diagnosis, STI, Vertically transmitted infection, GLOBE, Genital ulcer, Treponema pallidum, U.S. FDA, QAP, Laboratory, TGA, ISO 9001, Herpes simplex virus, Health, American Association, Health Canada, Ulcer, QAP (Colombia), News, Organization, CE, American Association for Clinical Chemistry, GUD, AACC, Company, FDA, Poster, Engineering, Antigen, Medical device, OTCQX, Vaccine, Treponema

GUDs are a current and growing global health concern, with over 20 million new cases each year.

Key Points: 
  • GUDs are a current and growing global health concern, with over 20 million new cases each year.
  • Microbix has overcome challenges in formulation and appears to be the first to develop a multiplex whole-workflow control for GUD assays.
  • Microbix creates proprietary biological products for human health, with over 100 skilled employees and sales approaching C$ 2.0 million per month.
  • Microbix is ISO 9001 and 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides CE marked products.

Knight Announces Normal Course Issuer Bid

Retrieved on: 
Tuesday, July 12, 2022
Laboratorio de Energía Solar Termoeléctrica, Annual report, TSX, Therapy, Intention, Company, GUD, GLOBE, Indian stock exchange, Toronto Stock Exchange, Calendar, Corporation, Nature, Security (finance), Knight, Uniting Medically Supervised Injecting Centre

MONTREAL, July 12, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company "), a leading pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the "TSX") of the Company's Notice of Intention to Make a Normal Course Issuer Bid ("NCIB").

Key Points: 
  • MONTREAL, July 12, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company "), a leading pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the "TSX") of the Company's Notice of Intention to Make a Normal Course Issuer Bid ("NCIB").
  • Knight also entered into an automatic share purchase plan with a broker in order to facilitate purchases of its common shares under the NCIB.
  • The price that Knight will pay for Common Shares in open market transactions will be the market price at the time of purchase.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com
    This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries.

Basilea announces Zevtera® (ceftobiprole) marketing authorization in Brazil

Retrieved on: 
Tuesday, July 12, 2022
Isavuconazonium, CAP, Marketing, MSSA, SIX Swiss Exchange, Communication, Gram-negative bacteria, Infection, HAP, TSX, Ceftobiprole, Methicillin-resistant Staphylococcus aureus, Patient, Ventilator-associated pneumonia, GUD, Adult, Community-acquired pneumonia, VAP, Hospital-acquired pneumonia, MRSA, MENA, Research, Mycosis, Pharmaceutical industry, Brazilian Health Regulatory Agency, Knight

David Veitch, Basileas Chief Executive Officer, stated: We are very pleased with the approval of Zevtera in Brazil.

Key Points: 
  • David Veitch, Basileas Chief Executive Officer, stated: We are very pleased with the approval of Zevtera in Brazil.
  • We look forward to working with Knight to make Zevtera available to patients in Brazil.
  • Knight has a strong local presence in Brazil, with a track record of successfully launching anti-infective brands in the country.
  • The grant of the marketing authorization triggered a milestone payment from Knight to Basilea.

Knight Therapeutics announces relaunch of AKYNZEO® in Brazil

Retrieved on: 
Monday, July 4, 2022
Intention, Annual report, Patient, CEO, Museo-laboratorio della Civiltà Contadina (Museum-workshop of the Peasant Culture), TSX, GLOBE, GUD, NCCN, Nausea, National Comprehensive Cancer Network, Vomiting, Dexamethasone, Physician, Nature, Palonosetron, Therapy, Pharmaceutical industry, Uniting Medically Supervised Injecting Centre, Knight, IQVIA

MONTREAL, July 04, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., is assuming full commercial activities and is relaunching AKYNZEO (netupitant / palonosetron) in Brazil.

Key Points: 
  • MONTREAL, July 04, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., is assuming full commercial activities and is relaunching AKYNZEO (netupitant / palonosetron) in Brazil.
  • According to IQVIA, sales of AKYNZEO in Canada and Brazil were approximately $7 million in 2021.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .
  • Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2021 as filed on www.sedar.com .

Knight to Present at the 2022 BIO International Convention in San Diego

Retrieved on: 
Tuesday, June 7, 2022
Laboratorio de Energía Solar Termoeléctrica, Annual report, BIO, Nature, GUD, Therapy, GLOBE, TSX, Industry, Intention, Biotechnology Innovation Organization, Fine chemical, Uniting Medically Supervised Injecting Centre

MONTREAL, June 07, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Amal Khouri, Chief Business Officer, is scheduled to present at the 2022 BIO International Convention on Tuesday, June 14, 2022 at 2:45 pm Pacific Time.

Key Points: 
  • MONTREAL, June 07, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Amal Khouri, Chief Business Officer, is scheduled to present at the 2022 BIO International Convention on Tuesday, June 14, 2022 at 2:45 pm Pacific Time.
  • The annual BIO International Convention, hosted by Biotechnology Innovation Organization (BIO), is the worlds largest industry gathering and brings together thousands of global biotechnology and biopharmaceutical leaders.
  • Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .